Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lantheus HoldingsLNTH +0.80%80 Return-on-Tangible-Asset is 35.53% as of Mar. 2026, which is 210% above its 10-year median of 11.46. GuruFocus rates LNTH with a GF Score™ of 80/100 and a GF Value™ of $90.73 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,009 Drug Manufacturers companies, Lantheus Holdings ranks better than 93.46% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Lantheus Holdings's annualizedNet Income for the quarter that ended in Mar. 2026 was $474 Mil. Lantheus Holdings's average total tangible assets for the quarter that ended in Mar. 2026 was $1,333 Mil. Therefore, Lantheus Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 35.53%.
The historical rank and industry rank for Lantheus Holdings's Return-on-Tangible-Asset or its related term are showing as below:
LNTH'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -16.03 Med: 11.46 Max: 42.44
Current: 18.9
During the past 13 years, Lantheus Holdings's highest Return-on-Tangible-Asset was 42.44%. The lowest was -16.03%. And the median was 11.46%.
LNTH's Return-on-Tangible-Asset is ranked better than 93.46% of 1009
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs LNTH: 18.90
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Lantheus Holdings Return-on-Tangible-Asset Related Terms
Lantheus Holdings Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Lantheus Holdings's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LNTH vs LQDA, HIMS, AMRX: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantheus Holdings Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 35.53% mean?
Lantheus Holdings (LNTH) has a Return-on-Tangible-Asset of 35.53% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Lantheus Holdings and its competitors. This is 210% above median its historical median of 11.46. According to the industry distribution chart, Lantheus Holdings ranks #66 out of 1009 companies in the Drug Manufacturers industry, placing it in the top 6.5%.
Is Lantheus Holdings' Return-on-Tangible-Asset too high?
Lantheus Holdings' current Return-on-Tangible-Asset of 35.53% is 210% above median its 10-year median of 11.46. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Lantheus Holdings' value of 35.53% is 1024.4% above this industry median. Based on the distribution chart, Lantheus Holdings ranks #66 out of 1009 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lantheus Holdings has a GF Score™ of 80/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lantheus Holdings' Return-on-Tangible-Asset compare to LQDA and HIMS?
According to the Drug Manufacturers industry distribution chart, Lantheus Holdings ranks #66 out of 1009 companies for Return-on-Tangible-Asset. This places Lantheus Holdings in the top 7% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.16. Lantheus Holdings' value of 35.53% is 1024.4% above this benchmark. While the company's 10-year median is 11.46 vs. the industry median of 3.16, Lantheus Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,009 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lantheus Holdings's current Return-on-Tangible-Asset of 35.53% is 1024.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Lantheus Holdings and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lantheus Holdings's current Return-on-Tangible-Asset is 35.53%, which is 210% above median its own 10-year median of 11.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantheus Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lantheus Holdings (LNTH) is currently considered Modestly Overvalued. The stock's GF Value™ is $90.73, compared to a current price of $105.11 — trading 15.8% above its estimated fair value. The current Return-on-Tangible-Asset is 35.53%, which is 210% above median its 10-year median of 11.46 and 1024.4% above the Drug Manufacturers industry median of 3.16. Lantheus Holdings' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Lantheus Holdings (LNTH), the current Return-on-Tangible-Asset is 35.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lantheus Holdings (LNTH) Overvalued in 2026?
Based on GuruFocus' analysis, Lantheus Holdings stock appears to be overvalued.
The current stock price of $105.11 is trading 15.8% above its estimated GF Value™ of $90.73.
GuruFocus considers Lantheus Holdings to be Modestly Overvalued.
Key valuation signals for LNTH:
Return-on-Tangible-Asset: 35.53% (210% above median its 10-year median of 11.46)
GF Value™: $90.73 vs. price of $105.11 (15.8% above fair value)
Industry Position: 1024.4% above the Drug Manufacturers median (#66 of 1009)
No single metric tells the full story. See the LNTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
80GF Score
Get the complete analysis for LNTH
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LNTH has been successfully added to your 
